THNR ETF — Amplify Weight Loss Drug & Treatment ETF

Amplify Weight Loss Drug & Treatment ETF (THNR)

Updated October 16, 2026.

THNR is an ETF. its distribution rate is 1.69%, its trailing-12-month yield is 1.69%, its expense ratio is 0.59%. Dividend Vision Distribution Safety Score™ is 50/100 (Unproven). Total return is -1.0% over the past 2.4 years, 48.9 points behind SPY at 47.9%.

Amplify Weight Loss Drug & Treatment ETF is an ETF that tracks an index of global companies positioned to benefit from weight loss drug development, including pharmaceutical manufacturers, combination therapy makers, and telehealth providers offering GLP-1 and related medications. The fund carries a modest expense ratio of 0.59% and maintains a modest current distribution rate. It does not have a regular distribution frequency, making it primarily suited for investors seeking equity exposure to the weight loss treatment sector rather than current income.

THNR performance versus SPY

Price and return data through 2026-10-16.

Total return is -1.0% over the past 2.4 years, 48.9 points behind SPY at 47.9%. Over the past year its total return — price change plus distributions reinvested — is 4.9%. Its deepest 1-year drawdown was 13.9%.

THNR key facts

Distribution Safety Score™

50 · Unproven

Issuer

Amplify ETFs

Asset type

ETF

Asset class

Equity

Inception date

05/20/2024

Expense ratio

0.59%

Distribution rate

1.69%

Distribution frequency

Annual

Trailing yield

1.69%

Last close

$24.50 (as of 2026-10-16)

AUM

$5,630,945

Average volume

664.0

Dividend

$0.413

Ex-dividend date

12/30/2025

Payment date

12/31/2025

Beta

0.6942

How Dividend Vision calculates yield and returns

Distribution rate (1.69%) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield (1.69%) is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: Amplify ETFs or company page; prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

THNR risks and drawbacks

THNR's current distribution rate is moderate, not a high-yield payout — the strategy is dividend quality more than maximum income. Payments are annual, so cash flow is lumpy versus a monthly fund. Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 13.9%.

Who may consider THNR — and who may not

It is a weaker fit for investors who need monthly cash flow (THNR pays annual); investors hunting double-digit covered-call yields; investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on THNR

• All tickers starting with T

Frequently asked questions

More securities from Amplify ETFs.